Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
3.060
-0.060 (-1.92%)
At close: Mar 6, 2026, 4:00 PM EST
3.056
-0.004 (-0.13%)
After-hours: Mar 6, 2026, 4:28 PM EST
Aclaris Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 7.83 | 18.72 | 31.25 | 29.5 | 6.64 | Upgrade
|
| Other Revenue | - | - | - | 0.26 | 0.12 | Upgrade
|
| Revenue | 7.83 | 18.72 | 31.25 | 29.75 | 6.76 | Upgrade
|
| Revenue Growth (YoY) | -58.19% | -40.09% | 5.03% | 340.05% | 4.30% | Upgrade
|
| Cost of Revenue | 59.93 | 49.04 | 114.25 | 89.77 | 48.53 | Upgrade
|
| Gross Profit | -52.1 | -30.32 | -83 | -60.02 | -41.77 | Upgrade
|
| Selling, General & Admin | 21.97 | 22.2 | 31.51 | 25.13 | 23.62 | Upgrade
|
| Operating Expenses | 21.97 | 22.2 | 31.51 | 25.13 | 23.62 | Upgrade
|
| Operating Income | -74.08 | -52.53 | -114.51 | -85.15 | -65.38 | Upgrade
|
| Interest & Investment Income | 7.64 | 7.95 | 8.51 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 3.82 | 1.91 | - | 2.95 | -1.14 | Upgrade
|
| EBT Excluding Unusual Items | -62.62 | -42.66 | -106 | -82.21 | -66.53 | Upgrade
|
| Merger & Restructuring Charges | - | - | -3.12 | - | - | Upgrade
|
| Other Unusual Items | -2.3 | -2.5 | 26.9 | -4.7 | -24.34 | Upgrade
|
| Pretax Income | -64.92 | -132.07 | -88.85 | -86.91 | -90.87 | Upgrade
|
| Income Tax Expense | - | - | -0.37 | - | - | Upgrade
|
| Earnings From Continuing Operations | -64.92 | -132.07 | -88.48 | -86.91 | -90.87 | Upgrade
|
| Net Income | -64.92 | -132.07 | -88.48 | -86.91 | -90.87 | Upgrade
|
| Net Income to Common | -64.92 | -132.07 | -88.48 | -86.91 | -90.87 | Upgrade
|
| Shares Outstanding (Basic) | 123 | 77 | 70 | 65 | 57 | Upgrade
|
| Shares Outstanding (Diluted) | 123 | 77 | 70 | 65 | 57 | Upgrade
|
| Shares Change (YoY) | 58.56% | 10.73% | 7.05% | 14.95% | 33.36% | Upgrade
|
| EPS (Basic) | -0.53 | -1.71 | -1.27 | -1.33 | -1.60 | Upgrade
|
| EPS (Diluted) | -0.53 | -1.71 | -1.27 | -1.33 | -1.60 | Upgrade
|
| Free Cash Flow | -47.22 | -20.2 | -79.63 | -68.17 | -52.44 | Upgrade
|
| Free Cash Flow Per Share | -0.39 | -0.26 | -1.14 | -1.04 | -0.92 | Upgrade
|
| Gross Margin | - | -161.99% | -265.60% | -201.74% | - | Upgrade
|
| Operating Margin | -946.52% | -280.59% | -366.44% | -286.21% | -967.08% | Upgrade
|
| Profit Margin | -829.58% | -705.48% | -283.15% | -292.11% | -1343.96% | Upgrade
|
| Free Cash Flow Margin | -603.42% | -107.89% | -254.84% | -229.13% | -775.65% | Upgrade
|
| EBITDA | -74.04 | -52.22 | -114.45 | - | -65.06 | Upgrade
|
| EBITDA Margin | - | -278.95% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.04 | 0.31 | 0.06 | - | 0.32 | Upgrade
|
| EBIT | -74.08 | -52.53 | -114.51 | -85.15 | -65.38 | Upgrade
|
| EBIT Margin | - | -280.59% | - | -286.21% | - | Upgrade
|
| Revenue as Reported | 7.83 | 18.72 | 31.25 | 29.75 | 6.76 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.